Edit |   |
---|---|
Antigenic Specificity | ACPP, Human |
Clone | REAL717 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | n/a |
Format | fluorescein (FITC) conjugate |
Size | 200 µL |
Concentration | n/a |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | ACPP Antibody, anti-human, FITC, REAdye_lease™. Clone REAL717 is an antibody fragment derived from the full ACPP antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL717 recognizes the human ACPP (acid phosphatase, prostate), also known as PAP (prostatic acid phosphatase. ACPP is a non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions. ACPP has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma. Isoform 2 of ACPP acts as a tumor suppressor of prostate cancer through dephosphorylation of ERBB2 and deactivation of MAPK-mediated signaling. It also generates adenosine from AMP which acts as a pain suppressor. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). | |
Immunogen | n/a |
Other Names | PAP (Prostatic Acid Phosphatase), 5'-NT, Ecto-5'-nucleotidase, TMPase, PAPf39 |
Gene, Accession # | n/a |
Catalog # | 130-126-572 |
Price | $410 |
Order / More Info | ACPP, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Graddis, T. J. et al. (2011) Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol 4 (3): 295-306. | Veeramani, S. et al. (2005) Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 12 (4): 805-822. |